Extracellular matrix scaffold technology for bioartificial pancreas engineering: State of the art and future challenges

Marcus Salvatori, Ravi Katari, Timil Patel, Andrea Peloso, Jon Mugweru, Kofi Owusu, Giuseppe Orlando

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Emergent technologies in regenerative medicine may soon overcome the limitations of conventional diabetes therapies. Collaborative efforts across the subfields of stem cell technology, islet encapsulation, and biomaterial carriers seek to produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes. These technologies rely on a robust understanding of the extracellular matrix (ECM), the supportive 3-dimensional network of proteins necessary for cellular attachment, proliferation, and differentiation. Although these functions can be partially approximated by biosynthetic carriers, novel decellularization protocols have allowed researchers to discover the advantages afforded by the native pancreatic ECM. The native ECM has proven to be an optimal platform for recellularization and whole-organ pancreas bioengineering, an exciting new field with the potential to resolve the dire shortage of transplantable organs. This review seeks to contextualize recent findings, discuss current research goals, and identify future challenges of regenerative medicine as it applies to diabetes management.

Original languageEnglish (US)
Pages (from-to)159-169
Number of pages11
JournalJournal of diabetes science and technology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Medical problems
Scaffolds
Extracellular Matrix
Pancreas
Regenerative Medicine
Technology
Bioengineering
Insulin
Biocompatible Materials
Stem cells
Encapsulation
Biomaterials
Stem Cells
Research Personnel
Cell Proliferation
Proteins
Research
Therapeutics

Keywords

  • Bioartificial pancreas
  • Diabetes mellitus
  • Extracellular matrix
  • Insulin
  • Regenerative medicine
  • Stem cells

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Cite this

Extracellular matrix scaffold technology for bioartificial pancreas engineering : State of the art and future challenges. / Salvatori, Marcus; Katari, Ravi; Patel, Timil; Peloso, Andrea; Mugweru, Jon; Owusu, Kofi; Orlando, Giuseppe.

In: Journal of diabetes science and technology, Vol. 8, No. 1, 01.01.2014, p. 159-169.

Research output: Contribution to journalReview article

Salvatori, Marcus ; Katari, Ravi ; Patel, Timil ; Peloso, Andrea ; Mugweru, Jon ; Owusu, Kofi ; Orlando, Giuseppe. / Extracellular matrix scaffold technology for bioartificial pancreas engineering : State of the art and future challenges. In: Journal of diabetes science and technology. 2014 ; Vol. 8, No. 1. pp. 159-169.
@article{524f0b011125486fa4eeed1e3cbb7e04,
title = "Extracellular matrix scaffold technology for bioartificial pancreas engineering: State of the art and future challenges",
abstract = "Emergent technologies in regenerative medicine may soon overcome the limitations of conventional diabetes therapies. Collaborative efforts across the subfields of stem cell technology, islet encapsulation, and biomaterial carriers seek to produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes. These technologies rely on a robust understanding of the extracellular matrix (ECM), the supportive 3-dimensional network of proteins necessary for cellular attachment, proliferation, and differentiation. Although these functions can be partially approximated by biosynthetic carriers, novel decellularization protocols have allowed researchers to discover the advantages afforded by the native pancreatic ECM. The native ECM has proven to be an optimal platform for recellularization and whole-organ pancreas bioengineering, an exciting new field with the potential to resolve the dire shortage of transplantable organs. This review seeks to contextualize recent findings, discuss current research goals, and identify future challenges of regenerative medicine as it applies to diabetes management.",
keywords = "Bioartificial pancreas, Diabetes mellitus, Extracellular matrix, Insulin, Regenerative medicine, Stem cells",
author = "Marcus Salvatori and Ravi Katari and Timil Patel and Andrea Peloso and Jon Mugweru and Kofi Owusu and Giuseppe Orlando",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1932296813519558",
language = "English (US)",
volume = "8",
pages = "159--169",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "1",

}

TY - JOUR

T1 - Extracellular matrix scaffold technology for bioartificial pancreas engineering

T2 - State of the art and future challenges

AU - Salvatori, Marcus

AU - Katari, Ravi

AU - Patel, Timil

AU - Peloso, Andrea

AU - Mugweru, Jon

AU - Owusu, Kofi

AU - Orlando, Giuseppe

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Emergent technologies in regenerative medicine may soon overcome the limitations of conventional diabetes therapies. Collaborative efforts across the subfields of stem cell technology, islet encapsulation, and biomaterial carriers seek to produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes. These technologies rely on a robust understanding of the extracellular matrix (ECM), the supportive 3-dimensional network of proteins necessary for cellular attachment, proliferation, and differentiation. Although these functions can be partially approximated by biosynthetic carriers, novel decellularization protocols have allowed researchers to discover the advantages afforded by the native pancreatic ECM. The native ECM has proven to be an optimal platform for recellularization and whole-organ pancreas bioengineering, an exciting new field with the potential to resolve the dire shortage of transplantable organs. This review seeks to contextualize recent findings, discuss current research goals, and identify future challenges of regenerative medicine as it applies to diabetes management.

AB - Emergent technologies in regenerative medicine may soon overcome the limitations of conventional diabetes therapies. Collaborative efforts across the subfields of stem cell technology, islet encapsulation, and biomaterial carriers seek to produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes. These technologies rely on a robust understanding of the extracellular matrix (ECM), the supportive 3-dimensional network of proteins necessary for cellular attachment, proliferation, and differentiation. Although these functions can be partially approximated by biosynthetic carriers, novel decellularization protocols have allowed researchers to discover the advantages afforded by the native pancreatic ECM. The native ECM has proven to be an optimal platform for recellularization and whole-organ pancreas bioengineering, an exciting new field with the potential to resolve the dire shortage of transplantable organs. This review seeks to contextualize recent findings, discuss current research goals, and identify future challenges of regenerative medicine as it applies to diabetes management.

KW - Bioartificial pancreas

KW - Diabetes mellitus

KW - Extracellular matrix

KW - Insulin

KW - Regenerative medicine

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84900563407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900563407&partnerID=8YFLogxK

U2 - 10.1177/1932296813519558

DO - 10.1177/1932296813519558

M3 - Review article

C2 - 24876552

AN - SCOPUS:84900563407

VL - 8

SP - 159

EP - 169

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 1

ER -